Mavenclad Is Merck KGaA Bright Spot As Q2 Sales Slip

 
• By Jo Shorthouse

With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.

Hourglass
Merck KGaA is playing the waiting game for profits to return

More from Business

More from Scrip